Four Cases of Hematologic Malignancy Following Radioactive Iodine Therapy for Thyroid Cancer.
10.3343/kjlm.2008.28.6.425
- Author:
Mijeong IM
1
;
Jin Kyung LEE
;
Young Joon HONG
;
Seok Il HONG
;
Hye Jin KANG
;
Im Il NA
;
Baek Yeol RYOO
;
Gi Jeong CHEON
;
Ha Na LEE
;
Yoon Hwan CHANG
Author Information
1. Department of Laboratory Medicine, Korea Cancer Center Hospital, Seoul, Korea. cyhlabo@kcch.re.kr
- Publication Type:English Abstract ; Case Report
- Keywords:
Thyroid cancer;
Radioisotope therapy
- MeSH:
Adult;
Chromosomes, Human, Pair 22;
Chromosomes, Human, Pair 5;
Chromosomes, Human, Pair 9;
Female;
Gene Deletion;
Hematologic Neoplasms/*diagnosis/genetics;
Humans;
Iodine Radioisotopes/*adverse effects/therapeutic use;
Leukemia, Radiation-Induced/*diagnosis/etiology;
Middle Aged;
Myelodysplastic Syndromes/diagnosis/genetics;
Neoplasms, Second Primary/*diagnosis/genetics;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis/genetics;
Thyroid Neoplasms/*radiotherapy;
Thyroidectomy;
Translocation, Genetic
- From:The Korean Journal of Laboratory Medicine
2008;28(6):425-429
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Ionizing radiation including I131 might produce chromosomal translocation, causing hematologic malignancy. The incidence of leukemia following radioactive iodine treatment for thyroid cancer has been reported to be approximately 0.1 to 2.0% in Western countries, whereas fewer cases have been reported in Korea. We hereby report four cases of secondary hematologic malignancy, who received iodine therapy for thyroid cancer after thyroidectomy: two cases of acute lymphoblastic leukemia with t(9;22)(q34;q11.2), a case of MDS with 5q deletion, and a case of MDS with normal karyotype. Three cases of hematologic malignancy have developed after cumulative dosage of less than 800 mCi. The treatment intervals in two cases were less than 12 months, and the other two cases had I131 therapy only once. Assessment of causality using the Naranjo probability scale for adverse drug reactions showed that a 'possible' relationship existed between the use of I131 and secondary hematologic malignancy in all of the four cases in this report.
